Source: StreetInsider

Press Release: Nurix : Nurix Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

SAN FRANCISCO, April 11, 2025 (GLOBE NEWSWIRE) -- Nurix Therapeutics, Inc. (Nasdaq: NRIX), a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of targeted protein degradation...

Read full article »
Annual Revenue
$25-100M
Employees
250-500
Arthur T. Sands's photo - President & CEO of Nurix

President & CEO

Arthur T. Sands

CEO Approval Rating

91/100

Read more